

# Investigating Viruses in Cells Used to Make Vaccines; and Evaluating the Potential Threat Posed by Transmission of Viruses to Humans

Principal Investigator: **Arifa S. Khan, PhD**

Office / Division / Lab: **OVRP / DVP / LR**

---

## General Overview

The emergence of pathogenic virus infections like influenza and HIV have created an urgent need for new vaccines.

Virus-based vaccines are made in living cells (cell substrates). Some manufacturers are investigating the use of new cell lines to make vaccines. The continual growth of cell lines ensures that there is a consistent supply of the same cells that can yield high quantities of the vaccine.

In some cases the cell lines that are used might be tumorigenic, that is, they form tumors when injected into rodents. Some of these tumor-forming cell lines may contain cancer-causing viruses that are not actively reproducing. Such viruses are hard to detect using standard methods. These latent, or "quiet," viruses pose a potential threat, since they might become active under vaccine manufacturing conditions. Therefore, to ensure the safety of vaccines, our laboratory is investigating ways to activate latent viruses in cell lines and to detect the activated viruses, as well as other unknown viruses, using new technologies. We will then adapt our findings to detect viruses in the same types of cell

substrates that are used to produce vaccines. We are also trying to identify specific biological processes that reflect virus activity.

These methods will enable FDA scientists to help manufacturers to determine whether their specific cell substrate is safe to use for vaccine production. The methods our laboratory are developing and testing will help to ensure the production of safe and effective vaccines in two ways: 1) FDA will be able to develop testing guidelines for manufacturers who use new cell substrates for producing vaccines; and 2) FDA will publish the new methods it develops in peer-reviewed scientific journals, thus making them readily accessible to all manufacturers.

We are also evaluating the risk of retrovirus infections in humans. (Retroviruses are RNA viruses that use an enzyme called reverse transcriptase (RT) to replicate; RNA is the decoded form of DNA). Simian foamy virus (SFV) can be transmitted from nonhuman primates (e.g., monkeys) to humans. Although there is no evidence that SFV causes disease, the virus can remain in a lifelong quiet state in the DNA after infection. Moreover, two individuals in Africa were recently found to be infected with both HIV-1 and SFV. Therefore, it is important to determine if SFV poses a threat to human health and to understand how the virus spreads in order to create strategies for controlling human infections. Such work will also help FDA to develop a new policy regarding blood donation by individuals working with nonhuman primates and implementing formal safety guidelines for people working with SFV-infected animals. We are also investigating the consequences of dual SFV and HIV-1 infection in the monkey model.

## Scientific Overview

Detection of latent viruses in cell substrates for vaccine safety. The urgent demand for vaccines against emerging diseases has necessitated the use of novel cell substrates. These include tumorigenic cells such as MDCK and CHO cells (for influenza virus vaccines), 293 and PER.C6 cells (for adenovirus-vectored HIV-1 and other vaccines), and tumor-derived cells such as HeLa cells (for HIV-1 vaccines).

The use of tumorigenic and tumor-derived cells is a major safety concern due to the potential presence of viruses such as retroviruses and oncogenic DNA viruses that could be associated with tumorigenicity. Therefore, detection of persistent, latent DNA viruses, and endogenous retroviruses in vaccine cell substrates is important for vaccine safety, particularly in the development of live viral vaccines, where there are no or minimal virus inactivation and removal steps during vaccine manufacturing.

Chemical induction is a rigorous method for evaluating the presence of endogenous retroviruses as well as some latent DNA viruses that have the potential to become active and produce infectious virus. This approach has been extensively used for mouse cells. We have optimized virus induction conditions in mouse cells using a standardized, highly sensitive, single-tube fluorescent PCR enhanced reverse transcriptase (STF-PERT) assay. We have further determined optimum conditions for activating latent DNA virus from a human cell line. We have extended the assay to develop a stepwise approach to induce and detect endogenous retroviruses and latent DNA viruses during evaluation of cell substrates for vaccine safety.

The chemical induction algorithm developed using these

positive control cell lines can be used to evaluate the safety of novel vaccine cell substrates for new vaccines. We are now investigating emerging technologies for broad virus detection to identify novel, induced and other unknown viruses. Additionally, we are investigating potential biomarkers for virus induction

In vitro and in vivo investigations to address retrovirus concerns in biologics. Simian foamy viruses (SFVs) are highly prevalent in all nonhuman primates (NHPs) and can infect humans by cross-species transmission. Although there is no evidence yet of disease with SFV, infectious virus persists in the host DNA. Therefore, we are trying to understand SFV latency and activation and factors involved in virus transmission, which will be important for managing SFV infections in humans.

We are also investigating potential interactions of SFV and SIV in the monkey model to predict the outcome of SFV and HIV-1 dual-infections in human cases, reported in Africa. Furthermore, our blood transfusion studies in monkeys regarding the risk of SFV transmission from infected blood donors to recipients will contribute to blood donation policy-making decisions.

---

## Publications

Genome Announc 2017 Aug 17;5(33):e00827-17

**Complete genome sequence of a naturally occurring simian foamy virus isolate from rhesus macaque (SFVmmu\_K3T).**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=57594](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=57594))

Nandakumar S, Bae EH, Khan AS

Genome Announc 2017 Aug 24;5(34):e00829-17

**Whole-genome sequence of the *Spodoptera frugiperda* Sf9 insect cell line.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=57659](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=57659))

Nandakumar S, Ma H, Khan AS

PDA J Pharm Sci Technol 2016 Nov-Dec;70(6):591-5

**Advanced Virus Detection Technologies Interest Group (AVDTIG): efforts for high throughput sequencing (HTS) for virus detection.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=55790](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=55790))

Khan AS, Vacante DA, Cassart JP, Ng SH, Lambert C, Charlebois RL, King K

Viruses 2016 Nov 23;8(11):318

**Eleventh International Foamy Virus Conference--meeting report.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=56237](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=56237))

Buseyne F, Gessain A, Soares MA, Santos AF, Materniak-Kornas M, Lesage P, Zamborlini A, Lochelt M, Qiao W, Lindemann D, Wohrl BM, Stoye JP, Taylor IA, Khan AS

Viruses 2015 Mar 31;7(4):1651-66

**Tenth International Foamy Virus Conference 2014--achievements and perspectives.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=51537](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=51537))

Materniak M, Kubis P, Rola-Luszczak M, Khan AS, Buseyne F, Lindemann D, Lochelt M, Kuzmak J

Vaccine 2015 Jan 1;33(1):73-5

**The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=50432](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=50432))

Chen RT, Carbery B, Mac L, Berns KI, Chapman L, Condit RC, Excler JL, Gurwith M, Hendry M, Khan AS, Khuri-Bulos N, Klug B, Robertson JS, Seligman S, Sheets R, Williamson AL

PDA J Pharm Sci Technol 2014 Nov-Dec;68(6):661-6

**New technologies and challenges of novel virus detection.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=50610](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=50610))

Khan AS, Ma H, Taliaferro LP, Galvin TA, Shaheduzzaman S

PDA J Pharm Sci Technol 2014 Nov-Dec;68(6):546-7

**Introduction and workshop summary: advanced technologies for virus detection in the evaluation of biologicals-applications and challenges.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=50846](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=50846))

Khan AS, Vacante DA

J Virol 2014 Jun 15;88(12):6576-85

**Identification of a novel rhabdovirus in Spodoptera frugiperda cell lines.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=48799](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=48799))

Ma H, Galvin TA, Glasner DR, Shaheduzzaman S, Khan AS

Viruses 2014 Apr 25;6(5):1876-96

**Evaluation of the broad-range PCR-electrospray ionization mass spectrometry (PCR/ESI-MS) system and virus microarrays for virus detection.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?)

id=48816)

Taliaferro LP, Galvin TA, Ma H, Shaheduzzaman S, Williams DK, Glasner DR, Khan AS

J Virol 2013 Aug;87(15):8792-7

**Identification of recombination in the envelope gene of simian foamy virus serotype 2 isolated from *Macaca cyclopis*.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=44253](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=44253))

Galvin TA, Ahmed IA, Shahabuddin M, Bryan T, Khan AS

Viruses 2013 Jun 6;5(6):1414-30

**Influence of naturally occurring simian foamy viruses (SFVs) on SIV disease progression in the rhesus macaque (*Macaca mulatta*) model.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=46065](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=46065))

Choudhary A, Galvin TA, Williams DK, Beren J, Bryant MA, Khan AS

J Virol 2013 Feb;87(4):2278-86

**No evidence of xenotropic murine leukemia virus-related virus transmission by blood transfusion from infected rhesus macaques.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=41950](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=41950))

Williams DK, Galvin TA, Gao Y, O'Neill C, Glasner D, Khan AS

PDA J Pharm Sci Technol 2012 Nov 1;66(6):502-11

**PDA/FDA Adventitious Agents and Novel Cell Substrates: Emerging Technologies and New Challenges, Nov. 3-4, 2011, Rockville, MD.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=42230](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=42230))

Khan AS, Lubiniecki A, King KE

Adv Virol 2011;2011:787394

**Xenotropic and other murine leukemia virus-related viruses in humans.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=40155](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=40155))

Khan AS, McClure M, Kubo Y, Jolicoeur P

Biologicals 2011 Nov;39(6):378-83

**Investigation of xenotropic murine leukemia virus-related virus (XMRV) in human and other cell lines.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=37459](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=37459))

Williams DK, Galvin TA, Ma H, Khan AS

PDA J Pharm Sci Technol 2011 Nov 1;65(6):627-33

**Current testing methods and challenges for detection of adventitious viruses.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=37827](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=37827))

Khan AS

PDA J Pharm Sci Technol 2011 Nov 1;65(6):685-9

**Detection of Latent Retroviruses in Vaccine-related Cell Substrates: Investigation of RT Activity Produced by Chemical Induction of Vero Cells.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=37837](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=37837))

Ma H, Khan AS

Vaccine 2011 Oct 26;29(46):8429-37

**Investigations of porcine circovirus type 1 (PCV1) in vaccine-related and other cell lines.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=36966](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=36966))

Ma H, Shaheduzzaman S, Williams DK, Gao Y, Khan AS



J Virol 2011 Jul;85(13):6579-88

**Chemical induction of endogenous retrovirus particles from the vero cell line of african green monkeys.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=25237](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=25237))

Ma H, Ma Y, Ma W, Williams DK, Galvin TA, Khan AS

Biologicals 2011 May;39(3):158-66

**Optimization of chemical induction conditions for human herpesvirus 8 (HHV-8) reactivation with 12-O-tetradecanoyl-phorbol-13-acetate (TPA) from latently-infected BC-3 cells.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=36338](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=36338))

Ma W, Galvin TA, Ma H, Ma Y, Muller J, Khan AS

PDA J Pharm Sci Technol 2010 Sep-Oct;64(5):426-31

**Testing considerations for novel cell substrates: a regulatory perspective.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=35628](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=35628))

Khan AS

PDA J Pharm Sci Technol 2010 Sep-Oct;64(5):451-7

**Regulatory considerations for raw materials used in biological products.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=35629](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=35629))

Khan AS

Transfusion 2010 Jan;50(1):200-7

**Role of neutralizing antibodies in controlling simian foamy virus transmission and infection.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=25019](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=25019))

Williams DK, Khan AS

Biologicals 2009 Jun;37(3):196-201

**Proposed algorithm to investigate latent and occult viruses in vaccine cell substrates by chemical induction.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=24141](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=24141))

Khan AS, Ma W, Ma Y, Kumar A, Williams DK, Muller J, Ma H, Galvin TA

Expert Rev Anti Infect Ther 2009 Jun;7(5):569-80

**Simian foamy virus infection in humans: prevalence and management.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=25248](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=25248))

Khan AS

J Virol Methods 2009 May;157(2):133-40

**Evaluation of different RT enzyme standards for quantitation of retroviruses using the single-tube fluorescent product-enhanced reverse transcriptase assay.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=22727](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=22727))

Ma YK, Khan AS

Transfusion 2006 Aug;46(8):1352-9

**Simian foamy virus infection by whole-blood transfer in rhesus macaques: potential for transfusion transmission in humans.**

([http://www.accessdata.fda.gov/scripts/publications/search\\_result\\_record.cfm?id=15762](http://www.accessdata.fda.gov/scripts/publications/search_result_record.cfm?id=15762))

Khan AS, Kumar D